Octapharma AG
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
5
Ending by 2030
Oct 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Feb 1 to 28, 2027 · next Feb 1
- 1 fee due Mar 1, 2027The maintenance fee for Recombinantly produced human factor VIII and IX (US 9,120,873) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
- 1 fee due Sep 29, 2027The maintenance fee for Process for Isolation and Purification of a Target Protein Free of Prion Protein (PRPSC) (US 9,296,799) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Method for Inactivation/Removal of Coagulation Factors by Precipitation (US 10,640,548) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,626,431 | Method for Improved Isolation of Recombinantly Produced Proteins In force · High confidence | In force | High confidence | |
| US 8,329,871 | Process of Purifying Coagulation Factor VIII In force · High confidence | In force | High confidence | |
| US 9,388,402 | Method for Improved Isolation of Recombinantly Produced Proteins In force · High confidence | In force | High confidence | |
| US 9,296,799 | Process for Isolation and Purification of a Target Protein Free of Prion Protein (PRPSC) In force · High confidence | In force | High confidence | |
| US 9,120,873 | Recombinantly produced human factor VIII and IX In force · From the USPTO record | In force | From the USPTO record | |
| US 9,371,355 | Process for production of fibrinogen In force · From the USPTO record | In force | From the USPTO record | |
| US 9,938,318 | Process for production of fibrinogen In force · From the USPTO record | In force | From the USPTO record | |
| US 8,871,439 | Serum-free stable transfection and production of recombinant human proteins in human cell lines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,901,597 | Method for Inactivation/Removal of Coagulation Factors by Precipitation In force · High confidence | In force | High confidence | |
| US 10,640,548 | Method for Inactivation/Removal of Coagulation Factors by Precipitation In force · High confidence | In force | High confidence |
Also on record, not counted in the 26: 17 lapsed for an unpaid fee · 17 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 5 abandoned · 19 no status recorded